How to manage changes in mood and cognitive function while taking Rasagiline

Rasagiline (Rasagiline) is a selective monoamine oxidaseB (MAO-B) inhibitor. It is commonly used to treat Parkinson's disease. It can increase dopamine levels in the brain, thereby improving motor symptoms. However, the dopamine system is also closely related to mood and cognitive functions. Therefore, during the use of rasagiline, some patients may experience mood swings, mild cognitive changes, or behavioral abnormalities, requiring comprehensive management and intervention.

First of all, some patients may experience symptoms such as anxiety, mild depression, or agitation in the early stages of taking the drug. This is due to the drug affecting the balance of neurotransmitters in the brain. These mood changes are usually temporary and may subside as the nervous system adjusts to the effects of the medication. Doctors should fully communicate with patients about expected effects and possible psychological reactions before taking medication. If necessary, they can combine psychological counseling or adjust the dosage to avoid excessive panic or unauthorized discontinuation of medication.

Secondly, some elderly patients or those with progressive disease may be accompanied by mild cognitive function changes such as decreased attention and memory while taking rasagiline. At this time, attention should be paid to distinguishing from the natural progression of Parkinson's disease, and dynamic assessment should be carried out in combination with neuropsychological assessment. If the cognitive impact is obvious, the doctor may adjust the drug plan as appropriate or consider incorporating cognitive auxiliary therapy. It is also recommended that family members strengthen supervision and support of the patient's daily life to prevent risks such as loss or mistaken medication.

Finally, in order to comprehensively manage emotional and cognitive problems during medication, it is recommended that patients establish a regular follow-up mechanism. Doctors can conduct emotional and cognitive status screenings every 3 to 6 months, in conjunction with lifestyle adjustments, such as maintaining a regular schedule, participating in social activities and moderate exercise, which can help stabilize the nervous state and slow down cognitive degradation. Through drug management and non-drug intervention in parallel, the quality of life and safety during rasagiline treatment can be guaranteed to the greatest extent.

Reference materials:https://www.drugs.com/